Life Science Investor Mandates
(Sept. 27 - Oct. 3
)
|
|
|
Seeks Novel Therapeutics and Diagnostics Across Neuroscience, Immunology, Inflammation, Rare Disease & Platform Technoogies
|
Invests in Therapeutics, Medical Devices, and Digital Health
|
Invests All Across Life Sciences and Healthcare, with Interests in Novel Technologies Including Genomics and Stem Cells
|
Invests in Medical Devices, Diagnostics, and Digital Health with Strong Interest in Technology-Based Products
|
|
|
It's almost time to open RESI Partnering for the upcoming New York event on November 5th. Hundreds of investors gathering to participate in RESI, and Partnering will run all day, providing entrepreneurs with up to 16 face to face meetings.
RESI's unique partnering system includes detailed profiles sourced from investor interviews by LSN's Investor Research team, and with this information attendees can direct their outreach to the attending investors who are the best fit for their technology, stage of development, and other relevant factors. With this basis in fit, entrepreneurs can make relevant new connections at RESI and start dialogues with investors who could help take their product to the next stage...
Confirmed Investors & Strategic Partners
As of October 4th, 2018
|
 |
 |
 |
We can't believe the RESI NYC Conference is only a month away! With this being our second year at NYC, the LSN team is truly excited about all of the innovation that we are gathering for the conference. We are particularly impressed by the global pool of applicants for the upcoming RESI NYC Innovation Challenge, with many startups from South America, Europe, the Middle East and Asia applying to be part of the Top 30 to showcase their technologies.
We have decided to extend the deadline to Monday, October 8th, to provide more time for startups who were interested in applying for this Innovation Challenge, but may not have had enough time to complete their applications. We are accepting submissions through our online application portal, and companies are also welcome to submit their application and supplementary materials to RESI@lifesciencenation.com...
|
 |
 |
 |
By
Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
LSN has studied the breakdown of investor participants in Redefining Early Stage Investments (RESI) conferences over the course of the last year, and we found over 1000 North America-based investors, over 250 Asia-based investors and over 150 Europe-based investors, most of whom attended more than one RESI event. The fundraising CEOs who seek out these investors come to RESI in similar numbers, making the investor-to-entrepreneur ratio at all RESI conferences about one to one, unheard of for a partnering conference. The RESI conference, due to its focus on early stage life science technologies, provides a present view of how the market is changing by bringing together the players on both side of the table - the early-stage buyers (investors and partners) and the early-stage sellers (scientist-entrepreneurs). As we all know, the healthcare arena and landscape is under dramatic change, with an enormous number new products and services that will become integrated into the healthcare industry.
When we look at these new products that entrepreneurs are showcasing at RESI, we see that they run the gamut from iterative (100 million + in market potential), to breakthrough (one billion +) to transformative (one trillion +). The LSN Company Platform additionally collates information on tens of thousands of life science companies around the world. As an example, we used the Company Platform to search for companies with products for surgery, and this is what we found:
|
 |
 |
|
Created & Produced by
|
 |
|
|
|